Compare DCGO & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCGO | KALA |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 55.8M |
| IPO Year | 2020 | 2017 |
| Metric | DCGO | KALA |
|---|---|---|
| Price | $0.60 | $1.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.38 | ★ $31.50 |
| AVG Volume (30 Days) | ★ 1.3M | 177.7K |
| Earning Date | 05-11-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $322,196,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.77 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.07 |
| 52 Week High | $1.78 | $20.58 |
| Indicator | DCGO | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 32.35 |
| Support Level | $0.47 | $0.32 |
| Resistance Level | $0.65 | $1.81 |
| Average True Range (ATR) | 0.05 | 0.33 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 91.21 | 1.18 |
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has two reporting segments: Mobile Health Services and Transportation Services. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.